chlorowodorek raloksyfenu

Jesteś tutaj: Dom / farmaceutyczne / Surowe proszki z utratą tłuszczu / chlorowodorek raloksyfenu

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

  • Producent: DEWAEL
  • Oznaczenie produktu: 99%+
  • Wygląd:light yellow powder
  • Miejsce pochodzenia: Chiny
  • Orzecznictwo: SGS,ISO9001, GMP
  • Minimalne zamówienie: 10sol
  • Szczegóły pakowania: 1 kg / folii torby,25kg / bęben lub wymagań
  • Czas dostawy: W ciągu 12 godzin po otrzymaniu płatności
  • Zasady płatności: western Union, MoneyGram,Bitcoin,Przelew bankowy
  • Wysyłka : EMS,DHL,Fedex,UPS,TNT i tak dalej.
  • Polityka: Ponowna wysyłka Polityki
  • możliwość dostaw: 500-600kg / miesiąc

Recenzje

Nie ma jeszcze żadnych opinii.

Be the first to review “Raloxifene Hydrochloride

Twoj adres e-mail nie bedzie opublikowany. wymagane pola są zaznaczone *


 

Top Quality Pharmaceutical Powder Raloxifene Hydrochloride CAS: 82640-04-8

 

Detale:

Nazwa:raloxifene hcl, Chlorowodorek raloksyfenu
CAS No.:82640-04-8
MF:C28H28ClNO4S
Use:antineoplastic
Wygląd:light yellow powder

 

Specyfikacja:

 

Nazwa produktu: Chlorowodorek raloksyfenu
CAS: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
Kategorie produktów: Active Pharmaceutical Ingredients;Raloxifene;Intracellular receptor;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;Pharmaceutical intermediate
Mol File: 82640-04-8.mol
mp 250-253DO
storage temp. -20°C Freezer
solubility DMSO: 28 mg/ml, soluble
form solid
color light yellow
CAS DataBase Reference 82640-04-8(CAS DataBase Reference)
Właściwości chemiczne Light-Yellow Solid
Stosowanie A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

 

Raloxifene Hydrochloride Description:

 

Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.

 

Raloxifene Hydrochloride Application:

 

Because of Raloxifene’s greater differences in its selectivity of Estrogen agonism and antagonism in different tissues in the body, there is ongoing investigation of its application in other diseases, including prostate cancer, acromegaly, uterine cancer, cardiovascular disease, and breast cancer.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.
Raloxifene is used to prevent and treat bone loss (osteoporoza) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.

 

———————————————————————————————————————————————————————————————————————————————————————-

Skontaktuj się teraz

 

Twoje imię (wymagany)

Twój email (wymagany)

Numer telefonu (wymagany)

Przedmiot

Twoja wiadomość